Quick Answer
VERTEX PHARMACEUTICALS INC / MA reported Revenue From Contract With Customer Excluding Assessed Tax of $12.00 billion for the year ending 2025.
- VERTEX PHARMACEUTICALS INC / MA showed an increase of +8.9% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from VERTEX PHARMACEUTICALS INC / MA's annual report (Form 10-K), filed with the SEC on February 13, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 10 years of available data (2016 to 2025), VERTEX PHARMACEUTICALS INC / MA's Revenue From Contract With Customer Excluding Assessed Tax has grown by 605.1%.
- Historical annual values: Fiscal year 2025: $12.00 billion | Fiscal year 2024: $11.02 billion | Fiscal year 2023: $9.87 billion | Fiscal year 2022: $8.93 billion | Fiscal year 2021: $7.57 billion | Fiscal year 2020: $6.21 billion | Fiscal year 2019: $4.16 billion | Fiscal year 2018: $3.05 billion | Fiscal year 2017: $2.49 billion | Fiscal year 2016: $1.70 billion.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: